Literature DB >> 26622771

Prognostic significance of combining VEGFA, FLT1 and KDR mRNA expression in lung cancer.

Shu-Dong Zhang1, Cian M McCrudden2, Hang Fai Kwok3.   

Abstract

Angiogenesis is important in cancer progression. Promising results in clinical trials have indicated that targeting vascular epidermal growth factor (VEGF) signaling may prolong lung cancer patient survival. In particular, various studies have implicated VEGFA as a potential prognostic marker in lung cancer, although prognostication using the expression of VEGF receptors (VEGFRs), such as fms-related tyrosine kinase 1 (FLT1; also known as VEGFR1) and kinase insert domain receptor (KDR; also known as VEGFR2), has produced varied results in different lung cancer studies. The present study aimed to investigate the prognostic significance of these three factors, alone or in combination. mRNA expression data were extracted from four independent lung cancer cohorts totaling 583 patients, and the association between mRNA expression and survival was investigated by performing statistical analyses. When VEGFA, FLT1 and KDR expression were considered alone, only VEGFA demonstrated a significant association with patient survival consistently across all four datasets (P<0.05). Patients with a high expression of VEGFA and one of the two receptors were associated with significantly worse survival than patients expressing low levels of VEGFA and the particular receptor (P<0.05). Notably, patients with a high level expression of all three genes in their tumor specimens were associated with a significantly shorter survival time compared with patients exhibiting a low level expression of one, two or all three genes (P<0.05). The results indicate that a high level of VEGFA expression and its receptors may be required for cancer progression. Therefore, these three factors should be considered together as a prognostic indicator for lung cancer patients.

Entities:  

Keywords:  angiogenesis; fms-related tyrosine kinase 1; kinase insert domain receptor; lung cancer; survival; vascular epidermal growth factor A

Year:  2015        PMID: 26622771      PMCID: PMC4533253          DOI: 10.3892/ol.2015.3415

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  26 in total

1.  Prognostic value of vascular endothelial growth factor and its receptor Flt-1 in squamous cell lung cancer.

Authors:  M Volm; R Koomägi; J Mattern
Journal:  Int J Cancer       Date:  1997-02-20       Impact factor: 7.396

2.  Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial.

Authors:  Martin Reck; Rolf Kaiser; Anders Mellemgaard; Jean-Yves Douillard; Sergey Orlov; Maciej Krzakowski; Joachim von Pawel; Maya Gottfried; Igor Bondarenko; Meilin Liao; Claudia-Nanette Gann; José Barrueco; Birgit Gaschler-Markefski; Silvia Novello
Journal:  Lancet Oncol       Date:  2014-01-09       Impact factor: 41.316

3.  miR-200 Inhibits lung adenocarcinoma cell invasion and metastasis by targeting Flt1/VEGFR1.

Authors:  Jonathon D Roybal; Yi Zang; Young-Ho Ahn; Yanan Yang; Don L Gibbons; Brandi N Baird; Cristina Alvarez; Nishan Thilaganathan; Diane D Liu; Pierre Saintigny; John V Heymach; Chad J Creighton; Jonathan M Kurie
Journal:  Mol Cancer Res       Date:  2010-11-29       Impact factor: 5.852

Review 4.  Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis.

Authors:  Daniel J Hicklin; Lee M Ellis
Journal:  J Clin Oncol       Date:  2004-12-07       Impact factor: 44.544

5.  KDR expression is associated with the stage and cigarette smoking of the patients with lung cancer.

Authors:  She-Juan An; Qiang Nie; Zhi-Hong Chen; Qiu-Xiong Lin; Zhen Wang; Zhi Xie; Shi-Liang Chen; Ying Huang; Ai-Ye Zhang; Jin-Feng Yan; Hong-Sui Wu; Jia-Ying Lin; Rong Li; Xu-Chao Zhang; Ai-Lin Guo; Tony S Mok; Yi-Long Wu
Journal:  J Cancer Res Clin Oncol       Date:  2007-05-04       Impact factor: 4.553

6.  The ratio of membrane-bound form Flt-1 mRNA to VEGF mRNA correlates with tumor angiogenesis and prognosis in non-small cell lung cancer.

Authors:  Kazumasa Takenaka; Hiromichi Katakura; Fengshi Chen; Eiji Ogawa; Masashi Adachi; Hiromi Wada; Fumihiro Tanaka
Journal:  Cancer Lett       Date:  2006-03-10       Impact factor: 8.679

7.  Prediction of recurrence-free survival in postoperative non-small cell lung cancer patients by using an integrated model of clinical information and gene expression.

Authors:  Eung-Sirk Lee; Dae-Soon Son; Sung-Hyun Kim; Jinseon Lee; Jisuk Jo; Joungho Han; Heesue Kim; Hyun Joo Lee; Hye Young Choi; Youngja Jung; Miyeon Park; Yu Sung Lim; Kwhanmien Kim; YoungMog Shim; Byung Chul Kim; Kyusang Lee; Nam Huh; Christopher Ko; Kyunghee Park; Jae Won Lee; Yong Soo Choi; Jhingook Kim
Journal:  Clin Cancer Res       Date:  2008-11-15       Impact factor: 12.531

8.  Autocrine regulation of glioblastoma cell cycle progression, viability and radioresistance through the VEGF-VEGFR2 (KDR) interplay.

Authors:  Petra Knizetova; Jiri Ehrmann; Alice Hlobilkova; Iveta Vancova; Ondrej Kalita; Zdenek Kolar; Jiri Bartek
Journal:  Cell Cycle       Date:  2008-08-12       Impact factor: 4.534

9.  Tumor induction of VEGF promoter activity in stromal cells.

Authors:  D Fukumura; R Xavier; T Sugiura; Y Chen; E C Park; N Lu; M Selig; G Nielsen; T Taksir; R K Jain; B Seed
Journal:  Cell       Date:  1998-09-18       Impact factor: 41.582

10.  The significance of combining VEGFA, FLT1, and KDR expressions in colon cancer patient prognosis and predicting response to bevacizumab.

Authors:  Shu-Dong Zhang; Cian M McCrudden; Chen Meng; Yao Lin; Hang Fai Kwok
Journal:  Onco Targets Ther       Date:  2015-04-15       Impact factor: 4.147

View more
  7 in total

1.  Lymphatics-associated genes are downregulated at transcription level in non-small cell lung cancer.

Authors:  Oksana Kowalczuk; Jerzy Laudanski; Wojciech Laudanski; Wieslawa Ewa Niklinska; Miroslaw Kozlowski; Jacek Niklinski
Journal:  Oncol Lett       Date:  2018-03-02       Impact factor: 2.967

2.  The Prognostic Value of the Combination of Low VEGFR-1 and High VEGFR-2 Expression in Endothelial Cells of Colorectal Cancer.

Authors:  Nicky D'Haene; Caroline Koopmansch; Yves-Rémi Van Eycke; Françoise Hulet; Justine Allard; Sarah Bouri; Sandrine Rorive; Myriam Remmelink; Christine Decaestecker; Calliope Maris; Isabelle Salmon
Journal:  Int J Mol Sci       Date:  2018-11-09       Impact factor: 5.923

3.  Expression levels of sonic hedgehog pathway genes and their targets are upregulated in early clear cell renal cell carcinoma.

Authors:  Anna Kotulak-Chrzaszcz; Agnieszka Rybarczyk; Jakub Klacz; Marcin Matuszewski; Zbigniew Kmiec; Piotr M Wierzbicki
Journal:  Int J Mol Med       Date:  2022-03-10       Impact factor: 4.101

4.  Clinical significance and prospective molecular mechanism of MALAT1 in pancreatic cancer exploration: a comprehensive study based on the GeneChip, GEO, Oncomine, and TCGA databases.

Authors:  Zu-Cheng Xie; Yi-Wu Dang; Dan-Ming Wei; Peng Chen; Rui-Xue Tang; Qian Huang; Jiang-Hua Liu; Dian-Zhong Luo
Journal:  Onco Targets Ther       Date:  2017-08-10       Impact factor: 4.147

5.  Novel mutational landscapes and expression signatures of lung squamous cell carcinoma.

Authors:  Donghai Xiong; Jing Pan; Yuxin Yin; Hui Jiang; Eva Szabo; Ronald A Lubet; Yian Wang; Ming You
Journal:  Oncotarget       Date:  2017-12-27

6.  Systematic large-scale meta-analysis identifies miRNA-429/200a/b and miRNA-141/200c clusters as biomarkers for necrotizing enterocolitis in newborn.

Authors:  Hong Liu; Yi-Biao Wang
Journal:  Biosci Rep       Date:  2019-09-24       Impact factor: 3.840

7.  The Influence of KDR Genetic Variation on the Efficacy and Safety of Patients With Advanced NSCLC Receiving First-Line Bevacizumab Plus Chemotherapy Regimen.

Authors:  Nan Geng; Jingwei Su; Zhikun Liu; Cuimin Ding; Shaonan Xie; Wenxia Hu
Journal:  Technol Cancer Res Treat       Date:  2021 Jan-Dec
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.